Global initiatives
Workshop presentation
Le Programme pour la vaccination à l’horizon2030 établit une vision et une stratégie mondiales ambitieuses pour les vaccins et la vaccination durant la décennie 20212030. Il s’appuie sur les...
Filip Dubovsky (MedImmune), Barney Graham (NIAID), Steve Hadley (Bill & Melinda Gates Foundation), Bruce Innes (PATH), Nina Russell (Bill & Melinda Gates Foundation), Erin Sparrow (WHO)
Edgar Brun (Norwegian Veterinary Institute), Dennis M. Dixon (NIAID), Johan Vekemans (WHO), Scott Hultgren (Professor, Washington University), Nithima Sumpradit (Thai FDA), Visanu Thamlikitkul...
Jean-Pierre Amorji (AH Consultancy), Maria Elena Bottazzi (Baylor College of Medicine), Andrea Cox (Johns Hopkins University), Suresh Jadhav (Serum Institute of India), Ruth Karron (Johns Hopkins...
Nihal Abeysinghe (Institute for Research and Development), Hartono Gunardi (Indonesia), Raymond Hutubessy (WHO), Odile Leroy (European Vaccine Initiative), Susan Wang (US CDC)
Martin Friede (WHO), Jennifer Gordon (NIAID), Punne Pitisuttithum (Mahidol University), John Tam (The HK Polytechnic University)
Annie Mo (NIAID), Chris Ockenhouse (PATH), Bernhards Ogutu Ragama (KEMRI), Andrew Pollard (University of Oxford), Lisa Wagar (Stanford Medicine)
Narendra Arora (INCLEN), David Durrheim (University of Newcastle), Pradeep Haldar (MOHFW, India), Keith Klugman (BMGF), Kate O’Brien (International Vaccine Access Center), Collins Tabu (Ministry of...
Paula Bryant (NIAID), Donald Drake (Sanofi Pasteur VaxDesign Corp.), Klaus Frueh (Vaccine & Gene Therapy Institute), Johan Neyts (University of Leuven)
Alejandro Cravioto (University of Mexico), Peter Dull (Bill & Melinda Gates Foundation), Martin Friede (Initiative for Vaccine Research, WHO), Lee Hall (NIAID), Jorge Kalil (University of Sao Paolo),...
Plenary 6 presentation
Peter Dull (Bill & Melinda Gates Foundation), Alejandro Ramirez Gonzalez (WHO/EPI), Pradeep Haldar (Ministry of Health and Family Welfare, India), Suresh Jadhav (Serum Institute of India, Ltd.),...
Plenary 5 presentation
Robert Breiman (Emory University), Suresh Jadhav (Serum Institute of India), Gagandeep Kang (Christian Medical College, Vellore), David Kaslow (PATH), Yot Teerawattanaon (Health Intervention and...
Plenary 4 presentation
Plenary 4 presentation
Norman W. Baylor (Biologics Consulting, Inc.), Carmen Rodriguez (WHO), Yeowon Shon (Seoul National Unviersity), Lucky Slamet (Badan Pom), Akanid Wapeewuttikorn (Thai FDA)
Plenary 3 presentation
Mahima Datla (Biological E. Limited), Kate Elder (MSF), Syarifah Lisa Munira (University of Indonesia), Martin Nicholson (UNIDO), Gerd Zettlemeisl (Hilleman Laboratories)
Plenary 2 presentation
Plenary 2 presentation
Plenary 2 presentation
Narendra Arora (INCLEN); Birgitte Giersing (WHO)Pradeep Halder (Ministry of Health and Family Welfare, India); Luan Lin (China CDC Suzhou); Folake Olaykinka (JSI); Anna Postovoitova (Ukraine); Awwal...
P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine development
Plenary 1 presentation
HIV – Kathryn Mngadi (Caprisa/HVTN), Punee Pitisittithum (Mahidol University); TB – Gerald Voss (Global HIV Vaccine Enterprise), Willem Hanekom (BMGF); Malaria – Fred Binka (University of...
Day 2 Keynote address
Defines the roles of participants in the Verification and Traceability System, the types of data generated and stored by the system, and the access each role has to the data.
The Nine Principles that parties implementing the Verification and Traceability System agree on.
2 page summary of the Verification and Traceability Initiative
This strategy brief outlines the urgent actions required by the
global community to vaccinate 70% of the world’s population
against COVID-19 by mid-2022. The goal is to substantially increase...
The meningitis road map has been designated as a flagship global strategy of the WHO’s Thirteenth General Programme of Work, 2019–2023 and is an essential component in achieving universal health...
La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du...
This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the...
Restructuring R&D to produce essential vaccines for infectious diseases we already recognize, and for those yet to emerge, is imperative. Powering Vaccine R&D: Opportunities for Transformation is a...
The Impact Report looks back at the challenges and progress of the ACT-Accelerator over the
last year. It highlights the accelerated actions taken by each of the ACT-Accelerator pillars
to ensure...
Keynote address delivered at the 2021 GVIRF meeting.
0:36 - Introduction.
3:43 - The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030, Kate O'Brien, WHO.
24:18 - Impact of COVID-19 on coverage and equity,...
P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030
Focus on zero dose children and subnational perspective; 4 priority areas of IA2030; What is being done; Evidence gaps and research questions
The impact on families of inequitable access, achieving COVID-19 vaccination, COVID-19 vaccine research: speed vs. equity, and the role of WHO in achieving vaccines equity.
0:00 - Anant Shah, Merck.
21:52 - Ahd Hamidi, Batavia Biosciences.
37:41 - Casey Selwyn, Bill & Melinda Gates Foundation.
54:32 - Block 1 Q&A, Antu Dey, Anant Shah, Ahd Hamidi, Casey...
0:00 - Ana Maria Henao =-Restrepo, WHO.
16:11 - Melanie Saville, CEPI.
34:20 - Barney Graham, NIAID/NIH.
54:35 - Block 1 Q&A, Helen Rees, Ana Maria Henao-Restrepo, Melanie Saville, Barney...
Measuring Behavioural and Social Determinants (BeSD) of vaccination and turning them into interventions
2:00 - Salmonella typhi, Sushant Sahastrabuddhe, IVI.
20:32 - Schistosomiasis, Robert Bergquist, Geospatial Health.
36:26 - HPV, Aimee Kreimer, NCI/NIH.
52:46 - Novel OPV, Ananda Bandyopadhyay,...
2:02 - HIV: Linda-Gail Bekker.
22:36 - TB: Ann Ginsberg.
42::50 - Malaria: Sodiomon B. Sirima.
56:49 - Block 1 Q&A, Norman Baylor, Linda-Gail Bekker, Ann Ginsberg.
1:23:28 - Block 2 Q&A, Lucky...
0:00 - Controlled human malaria infection—tool for accelerating vaccine development, Melissa Kapulu.
20:52 - Typhoid controlled human infection model, Andrew Pollard.
35:04 - Respiratory virus...
0:00 - Summary of the latest evidence and open research questions, Julie Leask.
16:10 - Evidence and lessons learned on social sciences analytics around vaccination in the Democratic
Republic of...
0:00 - A conversation on the challenges and opportunities for innovation in vaccination, Jon Abramson and Alejandro Cravioto.
9:24 - Transformative concepts for mass vaccination and pandemic...
What do we know, and how can we optimize vaccine-mediated protection for neonates?
Vaccine development has been transformed, now what is needed in the post-COVID era?
Landscape of typhoid conjugate vaccines, next steps and challenges. Rationale and landscape for non-typhoidal salmonella vaccines.
Immunization coverage and equity before and after COVID-19, reflections on equity and resiliency, and building back better
Key arguments for schistosomiasis vaccine development and update on vaccine candidates
Role of CHMI in malaria vaccine development, rationale for human infection studies in semi-immune adults in Kenya, work in progress and future developments
Lessons from rapid response platforms, the need for global equitable access, and building on rapid response platforms for the future
Why has HIV vaccine development been so challenging, update on HIV vaccine clinical development, and scientific advances fueling vaccine discovery
Options for pandemic influenza vaccines and challenges of universal influenza vaccine development
Overcoming challenges of new technology/vaccine introduction and country preparedness - case study of Kenya
Progress in nucleic acid vaccines, room for innovation, and where to go from here
What can the vaccine development community learn from COVID and how can it do better?
Strategic intent for Preferred Policy Profiles and proposed test cases
The following document outlines the current working structure and overall guiding principles of collaboration between the organisations involved in implementing COVAX. Building on existing bodies...
The ACT-Accelerator was set up to contain the COVID-19 pandemic faster and more efficiently by ensuring that successful diagnostics, vaccines and treatments are shared equitably across all...
For more than 40 years, PAHO’s Revolving Fund for Access to Vaccines, has provided access to safe and quality vaccines at affordable prices for Member States and Territories throughout the region....
Full Public Value of Vaccines as a driver of sustainable vaccine development and access
Results from vaccination surveys during Ebola outbreaks in the DRC and guidance for better use of social sciences analytics and vaccination in humanitarian settings
Viral-vectored vaccines against Ebola, Chikungunya, and COVID-19
Covid-19 has demonstrated that deployment challenges, under the compressed timelines of a pandemic, drive
technology innovation to facilitate rapid, mass, public health vaccination campaigns
Emerging vaccine issues and the road ahead
Why didn't one industrialized country company sell a new vaccine to LMICs at discounted prices? A case study of Hib vaccine in the mid-1990s
Emergence of novel coronavirus has resulted in global chaos within days of its first detection in Wuhan, China. To curb the spread of Covid- 19, stringent actions like lockdown and social distancing...
The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have...
SARS-CoV-2 has impacted health and immunization systems around the world
since early 2020 and is likely to alter vaccine markets for several years. This
report, based on country-reported purchase...